NCT02751424 - A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2016

Primary Completion Date

February 2, 2017

Study Completion Date

February 2, 2017

Conditions

Infections, Bacterial

Interventions

DRUG

GSK3342830

A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.

DRUG

Placebo

A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.

Trial Locations (1)

5000

GSK Investigational Site, Adelaide